The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Amyotrophic Lateral Sclerosis (ALS) Therapeutic Development Award, aimed at advancing research from preclinical therapeutic validation to FDA Investigational New Drug (IND)-enabling studies. This grant supports empirical, product-driven studies with a focus on lead compounds and requires proof-of-concept efficacy data in at least one preclinical model system of ALS. With an estimated total program funding of $9.6 million and the expectation of awarding four grants, eligible applicants include unrestricted entities such as non-profit organizations, for-profit companies, and academic institutions, with direct costs capped at $1.5 million for projects lasting up to three years. Interested applicants must submit a pre-application followed by a full application via eBRAP or Grants.gov by the deadline of July 10, 2024, and can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.